CJC-1295 w/o DAC
A modified GHRH analog without Drug Affinity Complex. CJC-1295 w/o DAC (also known as Mod GRF 1-29) is commonly researched alongside Ipamorelin for synergistic GH release.
Compound Profile
Pharmaceutical Data Sheet
Mechanism of Action
How CJC-1295 w/o DAC Works
CJC-1295 w/o DAC (Mod GRF 1-29) is a modified analog of endogenous growth hormone releasing hormone (GHRH), with 4 amino acid substitutions that stabilize the molecule against enzymatic degradation while maintaining GHRH-R selectivity. It amplifies the amplitude of natural GH pulses without disrupting pulsatility, and synergizes powerfully with GHRPs like Ipamorelin.
- Direct agonism at pituitary GHRH-R
- Increases GH gene transcription (GH1)
- Expands the pool of releasable GH granules
- Synergizes with GHS-R1a agonists (Ipamorelin)
- Gs-coupled receptor elevates cAMP
- PKA phosphorylates CREB for GH gene expression
- Potentiates IP3/calcium signaling from GHRPs
- Dual-pathway activation produces super-additive GH response
- Elevated GH drives hepatic IGF-1 synthesis
- IGF-1 mediates most anabolic GH effects
- IGFBP-3 elevation prolongs IGF-1 bioavailability
- Combined CJC + Ipa produces greater IGF-1 elevation than either alone
CJC-1295 w/o DAC binds the GHRH receptor (GHRH-R) on somatotrophs, activating Gs protein and adenylyl cyclase to elevate cAMP. PKA activation then drives GH gene transcription and primes GH granules for exocytosis. Unlike endogenous GHRH (half-life <7 min), Mod GRF 1-29 has a 30-min active window — enabling clinically meaningful GH axis stimulation.
Ionescu M & Frohman LA, J Clin Endocrinol Metab (2006): Pulsatile GH secretion stimulated by Mod-GRF(1-29).
Preclinical Findings
Research Models
Clinical Data
Synergistic GH Release with Ipamorelin Combination
Research demonstrates that combining a GHRH analog (CJC-1295 w/o DAC) with a GHRP (Ipamorelin) produces a synergistic GH response — the combination generates GH peaks 6–10× greater than either peptide alone, reflecting complementary intracellular signaling pathways (cAMP + calcium).
Bowers CY, Endocr Dev (2010): Synergy of GHRH + GHRP on GH secretion.
Human and rodent pharmacodynamic studies
Research Outcomes
Key Research Success Metrics
Safety Profile
Research Safety Notes
- No cortisol, prolactin, or ACTH elevation at studied doses
- Short 30-min active half-life limits duration of action — reduces systemic exposure
- Water retention possible at high doses due to downstream GH/IGF-1 activity
- Combining with Ipamorelin is the most common research protocol — both well-characterized
- No carcinogenic or mutagenic signals in preclinical studies
For research use only. GHRH analogs modulate the hypothalamic-pituitary axis. Pituitary feedback suppression is possible with chronic high-dose protocols.
About CJC-1295 w/o DAC
A modified GHRH analog without Drug Affinity Complex. CJC-1295 w/o DAC (also known as Mod GRF 1-29) is commonly researched alongside Ipamorelin for synergistic GH release.
All EVO Labs Research compounds are manufactured to research-grade standards and independently tested by Janoshik Analytical (Prague, est. 2013). The Certificate of Analysis for this compound includes full HPLC chromatography data, mass spectrometry confirmation, net purity percentage, and net content verification.
Research Use Only
This product is strictly for in vitro research and laboratory use only. Not for human or veterinary consumption. By purchasing, you confirm use in a controlled research setting.
